Articles tagged with Sars Cov 2
Researchers discovered molnupiravir works by causing polymerase to make sloppy copies of viral genome, rendering them useless. The drug has shown promising results in eliminating SARS-CoV-2 infectivity in newly diagnosed patients after five days of treatment.
Researchers are exploring SARS-COV-2 proteins as potential therapeutic targets for COVID-19. The review highlights the viral proteins' role in replication, structure, and interaction with host cells.
MIT researchers have generated the most accurate gene annotation of the SARS-CoV-2 genome, confirming six new protein-coding genes and discovering a rare gene-within-a-gene. The study also analyzed over 1,800 mutations, revealing regions that may help the virus evade the immune system.
Researchers propose targeting viral RNA with cylindrically-shaped molecules to block replication, effective against SARS-CoV-2 and HIV viruses. The approach could lead to broad-spectrum anti-viral drugs and provide a first line of defence against future pandemics.
A new study found that non-hospitalised SARS-CoV-2 infected individuals have a low risk of severe delayed effects, but still reported increased visits to general practitioners and outpatient clinics. The research highlights the need for clinicians to manage potential long-term conditions.
A global network of researchers has developed protocols for producing large quantities of SARS-CoV-2 proteins in high purity and stability. This allows laboratories to quickly and reproducibly study the virus and its mutants, facilitating research into potential treatments and vaccines.
Researchers found that GS-441524, a metabolite of remdesivir, inhibits the nsP3 protein's activity, which is important for virus replication and suppressing host cell defense. This discovery could lead to the development of new antiviral drugs effective against multiple viruses
A new pan-coronavirus vaccine has proven effective in protecting monkeys and mice from various coronavirus infections, including SARS-CoV-2 and its variants. The vaccine triggers neutralizing antibodies via a nanoparticle and targets a cross-reactive site of vulnerability on the spike protein.
Research reveals that as body mass index (BMI) increases, the risk of testing positive for SARS-CoV-2 also rises, especially among overweight and obese patients. The study analyzed data from over 26,000 patients tested for COVID-19 at a major medical center in Israel and found significant associations between BMI and viral infection risk.
The study found a significant association between the Pfizer-BioNTech BNT162b2 vaccine and decreased risk of symptomatic and asymptomatic SARS-CoV-2 infections in hospital employees. Hospital employees who received the vaccine had lower rates of infection compared to those who did not receive the vaccine.
Healthcare workers who received the Pfizer-BioNTech BNT162b2 vaccine had lower incidence of symptomatic and asymptomatic SARS-CoV-2 infections. The study found a significant association between vaccination with the BNT162b2 vaccine and reduced risk of SARS-CoV-2 infections among healthcare workers.
A study published in Experimental Physiology found increased stiffness of arteries in young adults after COVID-19, potentially leading to cardiovascular complications. The researchers are following the participants for 6 months to observe any improvements or long-term effects.
Researchers reconstructed the SARS-CoV-2 progenitor genome, finding it was circulating worldwide months before the first reported cases of COVID-19 in China. The team's findings provide a genetic common ancestor to all current infections and could aid molecular epidemiology detective work.
A team of researchers at the University of Texas at Austin has discovered that most SARS-CoV-2 antibodies target areas outside the receptor-binding domain, neutralizing the virus in cell cultures. This finding provides a promising lead for designing next-generation vaccines against variants and future coronaviruses.
Researchers from UNC Charlotte analyzed over 2,000 coronavirus genomes to clarify the origins of human infections. They found that bats are ancestral hosts of SARS-CoV-2, MERS-CoV, and other coronaviruses, with transmission occurring episodically.
A Wyss Institute collaboration used human organ chips to identify the antimalarial drug amodiaquine as a potent inhibitor of SARS-CoV-2. The research streamlines drug testing and provides a proof-of-concept for repurposing existing drugs for new medical applications, including future pandemics.
Researchers at Salk Institute confirm COVID-19 is primarily a vascular disease, revealing the virus' spike protein damages cells and disrupts molecular signaling. The findings provide new insight into the mechanism of disease and open doors for effective therapies.
A study by Imperial College London found that prior COVID-19 infection significantly enhances protection against the Kent and South Africa variants after a single dose of mRNA vaccine. In contrast, those without previous SARS-CoV-2 infection may not receive sufficient immune response, highlighting the importance of second doses.
A study published in PLOS Biology suggests that Lateral Flow Devices (LFDs) are more effective at detecting higher quantities of SARS-CoV-2 viral RNA, but struggle to identify infections in individuals with lower viral loads. The research highlights the need for frequent testing, particularly in early or late stages of infection.
Researchers discovered SARS-CoV-2 uses m6A modification to evade immune response, increasing viral replication and survival. Inhibiting METTL3 suppressed viral replication.
Researchers from Ural Federal University developed a new method for detecting SARS-CoV-2 using electrochemical biosensors made of emerging materials. The sensors offer high sensitivity, specificity, and portability, making them a promising tool for virus detection. Further research is needed to commercialize the technology.
Researchers have identified a SARS-CoV-2 variant that sacrifices tight binding to human cells in favor of evading the immune system, which could undermine current COVID-19 vaccines and therapies. The variant, B.1.351, has been found to reduce its binding to ACE2 receptors but decrease its binding to human antibodies.
Experts debate whether wearing masks outdoors can help reduce covid-19 transmission and encourage mask-wearing indoors. Some argue that normalising outdoor mask-wearing can bring benefits, while others believe efforts should focus on reducing indoor transmission.
A large meta-analysis of 17,687 individuals with diabetes found that those with more advanced diabetes have a higher risk of death from SARS-CoV-2. Men and older adults with diabetes were particularly at increased risk.
Researchers found that four hepatitis C drugs boost remdesivir's efficacy by up to tenfold in cell cultures. This combination therapy may provide an immediate treatment for unvaccinated individuals or those with waning immunity. The study aimed to develop an oral drug that inhibits SARS-CoV-2 like remdesivir.
Researchers created human intestinal cells to study SARS-CoV-2 infection process. The findings indicate the virus silences immune response in infected cells, suggesting new ways to treat it.
Researchers found that combining remdesivir with four HCV drugs boosts its antiviral activity by up to 10 times. This combination therapy could be a game changer for patients with COVID-19 who are not vaccinated or have waned immunity.
New research reveals SARS-CoV-2 can infect both neurons and astrocytes in the brain, leading to unpredictable neurological symptoms. Astrocytes play a key role in spreading the infection to neurons, contributing to severe effects in some patients.
Scientists from Würzburg developed CRISPR-Cas9 based diagnostic platform LEOPARD to detect multiple RNAs simultaneously, enabling simultaneous detection of viruses and other pathogens. The technology has the potential to revolutionize medical diagnostics for infectious diseases and rare genetic diseases.
Researchers have developed a new pooling strategy that maximizes the proportion of negative results after a single round of testing, allowing for prompt notification of results. This approach reduces the need for reagents and increases efficiency in healthcare settings.
Researchers evaluated SARS-CoV-2 variants and virus groupings in relation to disease severity. The study found notable associations between specific variants and more severe patient outcomes.
Australian researchers have identified neutralizing nanobodies that block the SARS-CoV-2 virus from entering cells, paving the way for alternative treatments. The discovery of a nanobody recognizing emerging global variants and original SARS virus suggests potential cross-protection against human coronaviruses.
A study found that maternal SARS-CoV-2 infection is associated with poorer health outcomes in perinatally exposed newborns. The study examined test result positivity rates and health outcomes among mothers infected during pregnancy or childbirth.
A new study has found that people can transmit SARS-CoV-2 to their cats during the pandemic, leading to mild or severe respiratory disease in felines. The researchers detected the virus in two domestic cats from households with suspected cases of COVID-19 and emphasized the need for monitoring human-to-cat transmission.
A new study by Johns Hopkins Medicine researchers found that mRNA vaccines for COVID-19 may provide protection against the latest variant strains and even the common cold. The vaccine-induced T cell response was found to be effective in recognizing the spike proteins of both SARS-CoV-2 and three common cold coronaviruses.
Researchers have identified a hidden region on the SARS-CoV-2 Spike protein that is masked by metabolites, making it inaccessible to antibodies. This finding highlights the importance of targeting this region in developing new vaccines.
Researchers found biliverdin and bilirubin, natural molecules present in the body, can suppress antibody binding to SARS-CoV-2. This discovery may help explain why some COVID-19 patients become severely ill despite having high levels of antibodies against the virus.
A modeling study suggests that rapid air exchanges can cause a spike in viral concentrations within 30 minutes and remain elevated for up to 90 minutes. Increasing outdoor air and strong filtration reduce transmission risk, but the effect of increased ventilation rate is less obvious.
Despite having clinically recovered from COVID-19, NBA players, staff, and vendors experienced persistent viral loads, indicating a high transmission risk. The study found that these individuals were more likely to transmit the virus to others, highlighting the need for continued precautions.
Researchers found that SARS-CoV-2 infection induces polyfunctional antibodies capable of neutralizing the virus and activating immune cells to destroy infected cells. Asymptomatic individuals also have these antibodies, but with slightly weaker responses.
Researchers simulated the COVID-19 epidemic's trajectory and found that even modest increases in evictions could lead to thousands of excess cases in Philadelphia, highlighting the need for renter protection policies to control the spread of SARS-CoV-2.
Researchers have developed an all-in-one test that integrates COVID-19 diagnosis, variant tracking, and co-infection detection into a single portable mini-laboratory. The NIRVANA test can detect SARS-CoV-2 mutations and report them simultaneously, making it a promising solution for rapid field-deployable detection.
Researchers have found that SARS-CoV-2 variants from minks can evade inhibition by COVID-19 antibodies, reducing immune control. The study showed that the Y453F mutation in the spike protein reduces the effectiveness of both therapeutic and human-made antibodies.
Scientists have developed a new COVID-19 vaccine that targets the spike protein of the virus, offering broad protection against existing and future strains. The vaccine's innovative approach uses a platform that can produce vaccines at very low cost, making it ideal for global vaccination efforts.
A new study suggests that pandemic eviction bans reduced infection rates and protected not only evicted individuals but also entire communities from the spread of COVID-19. The researchers found that without eviction bans, people who experience eviction or live with evictees have a higher risk of being infected, increasing transmission...
A liver transplant recipient was reinfected with SARS-CoV-2 111 days after initial diagnosis, using genomic sequencing to distinguish relapse from reinfection. Additionally, a study found people of color have substantially higher risks for hospitalization and intensive-level care for COVID-19 compared to White persons
A large population study found that taking probiotics, omega-3 fatty acids, multivits or vitamin D was associated with a lower risk of SARS-CoV-2 infection, with protective effects seen only among women. The study used data from the COVID-19 Symptom Study app and analyzed over 372,000 UK subscribers.
Researchers at Sanford Burnham Prebys have identified a set of human genes that help control SARS-CoV-2 infection, including interferon-stimulated genes (ISGs) that inhibit viral replication. The study provides new insights into the biology of the virus and suggests possible therapeutic options.
A new study from the NIH found that MK-4482 treatment significantly decreased virus levels and lung damage in hamsters infected with SARS-CoV-2. The treatment was effective when administered before or after infection, suggesting potential for mitigation of high-risk exposures.
A recent study published in Physics of Fluids reveals that the triangular shape of coronavirus spikes plays a crucial role in its ability to spread. The research, conducted by scientists at OIST and Queen's University, found that the spikes' lower rotational diffusivity enables the virus to better attach itself to objects and people.
A longitudinal study of over 3,000 young Marines found that past COVID-19 infection does not completely protect against reinfection. Young people with previous infection can still catch the virus and transmit it to others.
Research identifies SARS-CoV-2 variants emerging from immunocompromised hosts, leading to increased frequency of mutations. The study highlights the importance of monitoring genetic changes in SARS-CoV-2 to design effective vaccines and diagnostics.
A recent study published in The Lancet Respiratory Medicine found that past COVID-19 infection does not provide full immunity against reinfection, particularly among young people. Vaccination remains crucial to prevent reinfection and transmission, even among those who have had a previous infection.
Research from the Rhineland Study in Bonn, Germany, suggests that neutralizing antibodies against SARS-CoV-2 decline significantly within 4-5 months after infection. The study found that only about one-third of individuals testing positive for SARS-CoV-2 antibodies actually had specific antibodies against the virus.
The novel P.1 SARS-CoV-2 lineage emerged in November 2020, exhibiting 17 mutations, including those in the spike protein, making it more transmissible and lethal than its predecessor. Enhanced global genomic surveillance is critical to address increased transmission and immune evasion
A new study found that all six currently identified SARS-CoV-2 variants are widely spread across the Houston metropolitan area. Genome sequencing data showed geographically widespread dissemination of variants, with successful patient-to-patient transmission among communities.
Scientists identify 234 fragment compounds directly binding to SARS-CoV-2's Nsp3 Mac1 protein, mapping chemical motifs for potential antiviral drug development. The study lays out the next steps in designing and synthesizing more elaborate molecules with promising biological effects.
A recent NIH workshop highlighted the need for further research on post-acute COVID-19, a condition characterized by heterogeneous symptoms and long-term effects. The workshop presented important knowledge gaps in understanding the underlying pathophysiology of PASC.
Researchers created human induced pluripotent stem cells-derived intestinal organoids to study SARS-CoV-2's effects on the gut. This new model enables testing of potential therapeutics and identifying common disease mechanisms that can be targeted by drugs.
A new study finds that pre-pandemic children have higher frequencies of convergent B cell clones for SARS-CoV-2 and its variants, while adult blood shows few such clones. The research suggests that early childhood B cell clonal expansions may stimulate cross-reactive memory, leading to better responses to novel pathogens.